Posted by Michael Wonder on 07 Sep 2022
QOL Medical receives FDA approval of Sucraid (sacrosidase) oral solution single-use containers for patients with congenital sucrase-isomaltase deficiency
6 September 2022 - QOL Medical announced today that the US FDA approved Sucraid single-use containers for patients more than 33 lb (15 kg) with congenital sucrase-isomaltase deficiency.
Currently, Sucraid (sacrosidase) oral solution is the only pharmaceutical treatment for congenital sucrase-isomaltase deficiency in children and adults.
